Developmental therapeutics

515MO - A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)

Joline S. Lim, et al.


Triplet Cap+Ola+Durv is tolerable with evidence of PD and antitumor activity. Dose expansion at cap 200mg and 320mg OD are ongoing.


516MO - Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies

Haeseong Park, et al. 


The combination of eprenetapopt and pembrolizumab is safe and tolerable. Early signals of anti-tumor activity are observed. The expansion cohorts of the trial continue to enroll.


517MO - Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours

Natalie Cook, et al.


In patients with unselected cancers, RXC004 was safe and tolerated at doses up to 2mg/day, supporting phase 2 development in selected patients with Wnt pathway activated tumours. Studies will open in 2021.


518MO - Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors

Manish Sharma, et al.


Intermittent dosing of SY-5609 is tolerable above the MTD for continuous dosing with evidence of dose dependent PD effects observed. Early evidence of clinical activity, with durable SD and reduction in tumor size and markers, supports continued dose escalation with intermittent dosing.


519MO - Concordance analysis of treatment recommendations between central consensus and multidisciplinary tumor boards

Hidenori Kage, et al.


Our results indicate that sharing the information of matched therapy, particularly for that with low evidence level, may be needed to improve the quality of treatment recommendations by MTBs.


520MO - Using patient-reported outcomes (PROs) in dose-finding oncology trials (DFOT): Results from a global stakeholder survey and the National Cancer Research Institute (NCRI) Consumer Forum

Julia E. Lai-Kwon, et al.


Trialists and consumers reported minimal prior experience using PROs in DFOT but broadly supported their use in defining tolerable doses. Collaboration between key stakeholders and consumers should inform the research agenda in this area. Guidelines are needed to standardise PRO selection, analysis and reporting in DFOT.